Skip to main content
. 2019 Nov 19;2019:2429136. doi: 10.1155/2019/2429136

Table 1.

Baseline demographics and clinical characteristics of the study population.

Variable Conventional group (n = 22) PMMA group (n = 28) P value
Age (mean ± SD, years) 67.8 ± 7.4 68.9 ± 9.1 0.656
Gender 0.558
 Male 14 (63.6%) 20 (71.4%)
 Female 8 (36.4%) 8 (28.6%)
Type 2 DM 20 (90.9%) 24 (85.7%) 0.683
DM duration (mean ± SD, months) 96.3 ± 55.9 99.6 ± 47.3 0.822
DFU duration (mean ± SD, months) 6.5 ± 2.0 7.9 ± 1.8 0.008
Wagner classification 0.057
 Grade 3 13 (59.1%) 9 (32.1%)
 Grade 4 9 (40.9%) 19 (67.9%)
ABI (mean ± SD) 0.58 ± 0.10 0.57 ± 0.08 0.620
Nonreconstructable reasons 0.629
 Unpropitious vascular anatomy 14 (63.6%) 17 (60.7%)
 Calcific and fibrocalcific disease 5 (22.7%) 9 (32.1%)
 Patient refusal 3 (13.6%) 2 (7.1%)
BMI (mean ± SD, kg/m2) 26.3 ± 4.5 25.2 ± 4.1 0.391
Smoking 7 (31.8%) 17 (60.7%) 0.042
Alcohol abuse 7 (31.8%) 11 (39.3%) 0.585
Follow-up (mean ± SD, months) 16.4 ± 4.6 17.1 ± 4.1 0.575
Laboratory findings (mean ± SD)
 Glycemia (% (mmol/L)) 11.4 ± 6.1 11.0 ± 5.4 0.781
 HbA1C (% (mmol/mol)) 7.5 ± 1.4 7.8 ± 1.6 0.449
 WBC (×109/L) 9.6 ± 5.9 10.7 ± 4.8 0.467
 CRP (μmol/L) 63.6 ± 51.7 71.2 ± 59.8 0.639
 ESR (mm/hr) 55.8 ± 24.1 60.3 ± 23.7 0.518
 Albumin (g/L) 29.9 ± 10.6 28.7 ± 10.1 0.687
Comorbidities
 Hypertension 13 (59.1%) 21 (75.0%) 0.231
 Ischemic heart disease 9 (40.9%) 14 (50.0%) 0.522
 Peripheral neuropathy 20 (90.9%) 23 (82.1%) 0.444
 Nephropathy 13 (59.1%) 15 (53.6%) 0.696
 Retinopathy 10 (45.5%) 16 (57.1%) 0.412

PMMA: polymethylmethacrylate; DM: diabetes mellitus; DFU: diabetic foot ulcer; ABI: ankle-brachial index; BMI: body mass index; WBC: white blood cell; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate. Values are n (%) unless otherwise noted. Boldface indicated statistically significant difference.